Next 10 |
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain...
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing pl...
2024-05-10 07:31:44 ET More on IN8bio IN8bio gains after new preclinical data for nsCAR-T cell therapy platform Seeking Alpha’s Quant Rating on IN8bio Historical earnings data for IN8bio Financial information for IN8bio Read the full article ...
- Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue - Demonstrated potential of nsCAR platform to treat previously “undruggable” soli...
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, announced today that the first patient in its Phase 2 clinical trial evaluating INB-400 in patients with newly diagnosed...
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking p...
2024-04-11 08:16:21 ET More on pre-market losers stock Grifols: Q4 Was Positive, Still Too Many Question Marks Altice USA: Recent Refinancing Buys Time But Challenges Remain Altice USA, Inc. (ATUS) Q4 2023 Earnings Call Transcript Altice slips as Wells Fargo ...
2024-04-10 09:49:14 ET More on IN8bio Seeking Alpha’s Quant Rating on IN8bio Historical earnings data for IN8bio Financial information for IN8bio Read the full article on Seeking Alpha For further details see: IN8bio gains after new preclin...
2024-04-10 07:17:31 ET DENVER, Colo., Apr 10, 2024 ( 247marketnews.com )- IN8bio, Inc. (NASDAQ: INAB ) reported, after yesterday’s market close, new preclinical data from INB-300, its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell platform, which demo...
- Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an advanced technology for targeting hematologic and solid tumor cancers NEW YORK, April 09, 2024 (GLOB...
News, Short Squeeze, Breakout and More Instantly...
IN8bio Inc. Company Name:
INAB Stock Symbol:
NASDAQ Market:
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB) a clinical-stage biopharmaceutical company developing innovative gamma-de...
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain...
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing pl...